Aaron Camp

Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism

Key Points These 2 phase 3 trials assessed upacicalcet, an intravenous calcimimetic, in hemodialysis patients with secondary hyperparathyroidism. ≥30% reduction in intact parathyroid hormone levels occurred in 42% (Parathyroid Hormone [PTH] Attenuation Trial in Hemodialysis-1) an...